RNA - Atrium Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Hold
DETAILS
|
PRICE TARGET:
$25.00
DETAILS
HIGH:
$25.00
LOW:
$25.00
MEDIAN:
$25.00
CONSENSUS:
$25.00
UPSIDE:
90.99%
About Atrium Therapeutics, Inc. (http://www.atriumtherapeutics.com)
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. The company was incorporated in 2025 and is headquartered in San Diego, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Brendan Winslow | Chief Financial Officer | 1988 | – |
| Husam Younis | Chief Scientific Officer | 1974 | – |
| Kathleen Gallagher | President, CEO & Director | 1982 | – |
| Rocio Martin Hoyos | Chief Strategy Officer | 1983 | – |
| Stephanie Kenney | Chief Corporate Affairs Officer | 1978 | – |
| Steven George Hughes | Chief Medical Officer | 1968 | – |